EnVivo Pharmaceuticals initiates COGNITIV AD, a Phase 3 clinical trial program of encenicline (EVP-6124) in Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system (CNS) diseases, has announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer’s disease (AD). Read & Research Alzheimer’s More

Leave a Reply